Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer
- PMID: 22959577
- DOI: 10.1016/j.athoracsur.2012.07.042
Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer
Abstract
Background: Definitive chemoradiotherapy is associated with high local treatment failure rates, and surgical resection may be an appropriate salvage therapy. However, the efficacy and safety of salvage esophagectomy have not been elucidated fully. The clinical outcomes of salvage esophagectomy for locoregional failure after chemoradiotherapy were assessed.
Methods: Twelve patients who underwent salvage esophagectomy after chemoradiotherapy between January 2003 and November 2010 were included in this retrospective analysis. Baseline demographics and survivals of these patients were compared with 21 patients who did not receive salvage esophagectomy for locoregional failure only after chemoradiotherapy, identified from our own previous prospective trials.
Results: The median age was 62.5 years (range 50 to 69) and all patients had squamous cell carcinoma. The median radiation dose was 54.0 Gy (range 41.4 to 66.0) and the median interval between completion of chemoradiation and surgery was 8.0 months (range 2.0 to 32.9). There were no in-hospital deaths. Pulmonary complication was the most common postoperative morbidity (42%), and anastomotic leakage occurred in 1 patient (8%). With a median follow-up period of 29.3 months (range 5.8 to 73.0), the overall 3-year survival rate was 58%. Patients with early pathologic stage disease (T1/2 and N0) showed significantly prolonged survival (p=0.03) compared with those with advanced pathologic stage (T3/T4 or N1). Patients with salvage esophagectomy had prolonged event-free survival and overall survival compared with those patients with locoregional failure who received primary chemotherapy or boost radiotherapy (p<0.001).
Conclusions: While salvage esophagectomy for locoregional failure after chemoradiotherapy should be employed with great caution, it appears to be a feasible and effective therapeutic option for highly selected patients, especially with early pathologic stage disease. Salvage esophagectomy can be recommended as the only current curative treatment option for patients with locoregional failure after chemoradiotherapy.
Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Comment in
-
Invited commentary.Ann Thorac Surg. 2012 Dec;94(6):1868-9. doi: 10.1016/j.athoracsur.2012.09.005. Ann Thorac Surg. 2012. PMID: 23176905 No abstract available.
Similar articles
-
Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma.J Thorac Cardiovasc Surg. 2009 Jan;137(1):49-54. doi: 10.1016/j.jtcvs.2008.05.016. J Thorac Cardiovasc Surg. 2009. PMID: 19154902
-
Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma.Ann Thorac Surg. 2012 Oct;94(4):1126-32; discussion 1132-3. doi: 10.1016/j.athoracsur.2012.05.106. Epub 2012 Aug 24. Ann Thorac Surg. 2012. PMID: 22921233
-
Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1484-93. doi: 10.1016/j.ijrobp.2004.05.056. Int J Radiat Oncol Biol Phys. 2004. PMID: 15590179
-
Salvage oesophagectomy after local failure of definitive chemoradiotherapy.Br J Surg. 2007 Sep;94(9):1059-66. doi: 10.1002/bjs.5865. Br J Surg. 2007. PMID: 17657720 Review.
-
Indications and outcome of salvage surgery for oesophageal cancer.Eur J Cardiothorac Surg. 2008 Jun;33(6):1117-23. doi: 10.1016/j.ejcts.2008.01.056. Epub 2008 Mar 14. Eur J Cardiothorac Surg. 2008. PMID: 18342532 Review.
Cited by
-
Comparison of the effects of radiotherapy doses of 50.4 Gy and 60 Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.Esophagus. 2020 Apr;17(2):122-126. doi: 10.1007/s10388-019-00711-x. Epub 2020 Jan 7. Esophagus. 2020. PMID: 31912332 Free PMC article.
-
The use of neoadjuvant therapy for resectable locally advanced thoracic esophageal squamous cell carcinoma in an analysis of 5016 patients from 305 designated cancer care hospitals in Japan.Int J Clin Oncol. 2018 Feb;23(1):81-91. doi: 10.1007/s10147-017-1178-y. Epub 2017 Aug 9. Int J Clin Oncol. 2018. PMID: 28795280
-
Prognostic Factors of Salvage Esophagectomy for Residual or Recurrent Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy.World J Surg. 2018 Sep;42(9):2887-2893. doi: 10.1007/s00268-018-4536-7. World J Surg. 2018. PMID: 29423738
-
Clonal Expansion of Tumor-Infiltrating T Cells and Analysis of the Tumor Microenvironment within Esophageal Squamous Cell Carcinoma Relapsed after Definitive Chemoradiation Therapy.Int J Mol Sci. 2021 Jan 22;22(3):1098. doi: 10.3390/ijms22031098. Int J Mol Sci. 2021. PMID: 33499345 Free PMC article.
-
Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma.Ann Gastroenterol Surg. 2020 Jun 22;4(5):490-497. doi: 10.1002/ags3.12364. eCollection 2020 Sep. Ann Gastroenterol Surg. 2020. PMID: 33005843 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical